🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

659 results for “MS” Clear

  1. MK-2214

    Merck KGaA, Darmstadt, Germany

    Early Alzheimer's Disease

    phase 2 mab active

    1 trial

  2. MK-6194

    Merck KGaA, Darmstadt, Germany

    Systemic Lupus Erythematosus

    phase 2 mab terminated

    1 trial

  3. MSC

    Shandong University

    Type 2 Diabetes

    phase 2 mab active

    1 trial

  4. MSC

    The Children's Hospital of Zhejiang University School of Medicine

    BPD - Bronchopulmonary Dysplasia

    phase 2 small molecule active

    1 trial

  5. MSC and PRP

    Hospital Authority, Hong Kong

    Type 1 Diabetes Mellitus

    phase 2 mab active

    1 trial

  6. MSC-NTF cells transplantation (IM)

    BRAINSTORM CELL THERAPEUTICS INC.

    Amyotrophic Lateral Sclerosis

    phase 2 mab completed

    1 trial

  7. MSCAT-THAC Placebo, Allogeneic Mesenchymal stromal cells derived from adipose tissue thawed and cultured

    Pari Pharma GmbH

    Systemic sclerosis

    phase 2 small molecule active

    1 trial

  8. MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF

    BRAINSTORM CELL THERAPEUTICS INC.

    Amyotrophic Lateral Sclerosis

    phase 2 mab completed

    1 trial

  9. Medical Collagen Membrane with MSC

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Wounds

    phase 2 other active

    1 trial

  10. Miransertib

    Merck KGaA, Darmstadt, Germany

    PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome

    phase 2 small molecule terminated

    1 trial

  11. Mivelsiran, Placebo

    Alnylam Netherlands B.V.

    Cerebral Amyloid Angiopathy (CAA) is a neurological condition in which amyloid proteins build up in the walls of blood vessels in the brain, causing problems such as bleeding into the brain

    phase 2 small molecule active

    1 trial

  12. Modakafusp Alfa

    Teva Pharma GmbH

    Neoplasms

    phase 2 small molecule terminated

    1 trial

  13. Modakafusp Alfa

    Teva Generics B.V

    Neoplasms

    phase 2 small molecule terminated

    1 trial

  14. Nenocorilant 200 mg

    CORCEPT THERAPEUTICS INC

    Neoplasms

    phase 2 small molecule active

    1 trial

  15. Nimotuzumab

    The First People's Hospital of Lianyungang

    Esophageal Neoplasms

    phase 2 small molecule active

    1 trial

  16. Nivo 240 mg and Rela 80 mg per vial, OPDIVO 10 mg/mL concentrate for solution for infusion., Relatlimab

    Bristol-Myers Squibb Australia Pty Ltd

    Neoplasms by site

    phase 2 small molecule active

    1 trial

  17. Nivolumab Injection [Opdivo]

    The First People's Hospital of Lianyungang

    Neoplasms

    phase 2 small molecule active

    1 trial

  18. Nivolumab Subcutaneous, BMS986482, FDC Nivolumab + Relatlimab + rHuPH20 Injection, BMS986482, BEVACIZUMAB

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  19. NurOwn (MSC-NTF cells)

    BRAINSTORM CELL THERAPEUTICS INC.

    Multiple Sclerosis, Chronic Progressive

    phase 2 mab completed

    1 trial

  20. ONDANSETRON , APREPITANT , PALONOSETRON, COMBINATIONS, PALONOSETRON , Lagipra, GRANISETRON , DEXAMETHASONE , 0.9% sodium chloride

    Eli Lilly Co.

    Nausea, Drug-Related Side Effects and Adverse Reactions, Vomiting, Neoplasms

    phase 2 small molecule active

    1 trial

  21. OPDIVO 10 mg/mL concentrate for solution for infusion., Ipilimumab, OPDIVO 10 mg/mL concentrate for solution for infusion., DARZALEX 20 mg/mL concentrate for solution for infusion, Relatlimab, Relatlimab

    Bristol-Myers Squibb Australia Pty Ltd

    MSI Negative Colorectal Cancer, MSI Positive Colorectal Cancer

    phase 2 small molecule active

    1 trial

  22. OXALIPLATIN, ETOPOSIDE, CISPLATIN, CALCIUM FOLINATE, CAPECITABINE, IRINOTECAN, PACLITAXEL, FLUOROURACIL, TRABECTEDIN, DOCETAXEL, IFOSFAMIDE, PACLITAXEL ALBUMIN-BOUND, DOXORUBICIN, MITOTANE, CARBOPLATIN, GEMCITABINE

    Ningbo Cancer Hospital

    Patients with dMMR/MSI (non-colorectal/non-endometrial) locally advanced or metastatic cancer

    phase 2 small molecule active

    1 trial

  23. OXALIPLATIN, PANITUMUMAB, Lonsurf 15 mg/6.14 mg film-coated tablets, Lonsurf 20 mg/8.19 mg film-coated tablets, BEVACIZUMAB, NIVOLUMAB, TRASTUZUMAB

    Ningbo Cancer Hospital

    Patients with pMMR/MSS metastatic adenocarcinoma of the colon or rectum or gastroesophageal cancer (lower esophagus, gastroesophageal junction and gastric) and with known dihydropyrimidine dehydrogenase (DPD) deficiency defined as plasma uracil concentration ≥16 ng/ml, who undergo first-line treatment

    phase 2 small molecule active

    1 trial

  24. Obatoclax mesylate (GX15-070MS)

    Teva Pharma GmbH

    Hodgkin's Lymphoma

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources